CION Ameerpet
AITL is a rare, aggressive T-cell lymphoma that often behaves partly like an immune disorder. This guide explains what angioimmunoblastic lymphoma is, how it is diagnosed, and how CION's haematology and oncology team plans coordinated care.
Angioimmunoblastic T-cell lymphoma — usually shortened to AITL, and sometimes called angioimmunoblastic lymphoma — is a rare and aggressive form of peripheral T-cell lymphoma. It develops from a specialised immune cell called the follicular helper T-cell. Although it is uncommon overall, AITL is one of the more frequently diagnosed T-cell lymphomas in adults, and it mostly affects people in later middle age and beyond.
What sets AITL apart is that it does not behave like a "typical" cancer alone. Because it arises from an immune-regulating cell, it disturbs the immune system across the body — so people often have fevers, skin rashes, itching and abnormal blood tests alongside enlarged lymph nodes. This immune-like picture is why AITL is sometimes mistaken at first for an infection or an autoimmune disease, and why an expert pathology review matters so much.
This guide explains AITL's symptoms, how it is diagnosed, how it is treated and its prognosis. For the wider picture, see our Lymphoma hub, the broader T-cell lymphoma overview, and our Lymphoma Treatment in Hyderabad page.
AITL is now grouped with a wider family called "nodal T-cell lymphomas with a follicular helper T-cell (TFH) phenotype" in the modern classification of lymphomas. This reflects the discovery that AITL, and several related tumours, all originate from the same specialised follicular helper T-cell and share molecular features such as expression of CD10, PD-1 and CXCL13. This is why immunohistochemistry — not the microscope appearance alone — is essential to pin down the exact subtype. (Source: WHO classification of haematolymphoid tumours, as referenced in NCCN and ESMO T-cell lymphoma guidelines.)
AITL sits at the crossroads of cancer and immune dysfunction. These features help explain why it is diagnosed and managed differently from the common B-cell lymphomas.
Because AITL comes from an immune-regulating T-cell, it disrupts the body's immune balance. This produces fevers, rashes, autoimmune-type blood results and abnormal antibodies — features you would not expect from most other lymphomas.
AITL commonly presents at an advanced stage, with widespread lymph-node involvement and often an enlarged liver and spleen or bone-marrow involvement. This shapes treatment towards systemic (whole-body) therapy from the outset.
Many AITL biopsies contain Epstein-Barr virus-positive B-cells within the tumour environment. The lymphoma is a T-cell cancer, but this EBV background is a recognised feature and part of what the pathologist looks for.
AITL is one of several closely related T-cell lymphomas. Distinguishing it from PTCL and other subtypes needs immunohistochemistry for follicular helper T-cell markers — a job for an experienced haematopathologist.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received an angioimmunoblastic T-cell lymphoma diagnosis, want to understand your reports, or need a second opinion before treatment? CION's haematology and oncology team is here.
AITL symptoms often come on relatively quickly and reflect both the lymphoma and the immune disturbance it causes. Because it is usually advanced when found, symptoms tend to be systemic rather than confined to one area. Common features include:
These features overlap with many infections and autoimmune conditions, so AITL is easy to miss early. A cluster of these signs — especially persistent lymph-node swelling with fevers and a rash — warrants prompt specialist assessment and a biopsy. Speak to a CION lymphoma specialist if you have these signs or a confirmed diagnosis.
Confirming AITL — and separating it from its close T-cell relatives — needs a careful, step-by-step pathway. CION delivers the biopsy coordination, bone-marrow exam, molecular and immunohistochemistry testing, and multidisciplinary review directly.
The single most important test is a surgical excision biopsy of a whole lymph node. A small needle sample is often not enough for T-cell lymphomas, because the diagnosis depends on seeing the tumour's architecture and running a full panel of stains. This is why an intact node is preferred whenever possible.
An expert haematopathologist examines the tissue for the hallmark features of AITL: a background of proliferating small blood vessels and tumour cells that express follicular helper T-cell markers — CD10, BCL6, PD-1 and CXCL13. Testing for Epstein-Barr virus (EBV) within the tissue is standard, as is clonality testing. These molecular markers are testing concepts that confirm the subtype and distinguish AITL from other T-cell lymphomas.
Once AITL is confirmed, a PET-CT scan maps how widely it has spread, and a bone-marrow examination checks for marrow involvement. Blood tests assess organ function and markers used in prognosis. This staging information — combined with your age and fitness — guides the treatment plan discussed at the tumour board. See how staging feeds into treatment on our Lymphoma Treatment in Hyderabad page.
For T-cell lymphomas like AITL, a surgical excision biopsy of a whole lymph node is strongly preferred over a small needle sample. The diagnosis depends on seeing the tumour's architecture and running a broad panel of immunohistochemistry stains — something a tiny core often cannot provide. Getting the right biopsy first time avoids repeat procedures and delays. (Source: NCCN and ESMO peripheral T-cell lymphoma guidelines.)
Because AITL is usually advanced and aggressive, treatment is centred on systemic therapy that reaches disease throughout the body. Every case is reviewed by CION's multidisciplinary tumour board before the plan is set. The main building blocks are:
First-line treatment for AITL is usually a course of combination chemotherapy, delivered directly by CION's medical oncology and haematology team. We describe therapy here by class and purpose rather than by brand names — the exact regimen is individualised to your stage, age and fitness, and is explained in full on the Lymphoma Treatment in Hyderabad page.
For fit patients who achieve a good response, doctors often consider consolidating that remission with an autologous stem-cell transplant to reduce the chance of relapse. Transplant is a coordinated referral through accredited partner facilities — it is not performed in-house — while CION manages the chemotherapy, work-up, supportive care and follow-up around it.
For relapsed or resistant AITL, treatment may switch to a different drug class — including antibody-based immunotherapy and targeted agents that act on specific pathways in T-cell lymphoma. Antibody and immunotherapy treatments are delivered directly at CION. Where appropriate, a clinical-trial option may also be discussed.
Radiation therapy (IMRT) has a more limited, situation-specific role in AITL — for example to a bulky or troublesome site — and is delivered directly by CION. Because AITL disturbs the immune system, careful supportive care (infection prevention, transfusion support and symptom control) and survivorship follow-up are an important part of the plan.
AITL is an aggressive lymphoma, and as a group the T-cell lymphomas tend to have a less favourable outlook than the common B-cell lymphomas. To put this in context with published figures (per NCCN and ESMO):
These are published, attributed figures — not CION-specific statistics — and outcomes vary widely from person to person. Age, general fitness, stage, how well the disease responds to first-line treatment, and whether a stem-cell transplant is possible all influence the outlook, and fit patients who reach a good remission can do considerably better than the group average. Your own prognosis should always be discussed with your treating oncologist. For related subtypes, see our overviews of cutaneous T-cell lymphoma, anaplastic large cell lymphoma and extranodal NK/T-cell lymphoma.
Because AITL is rare and easily confused with other conditions, a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. You can also explore our best lymphoma doctors in Hyderabad and best lymphoma hospital in Hyderabad pages. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if the subtype markers or EBV status have not yet been confirmed on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon, aggressive type of peripheral T-cell lymphoma that arises from a specialised T-cell (the follicular helper T-cell). It is one of the more frequently diagnosed T-cell lymphomas in adults, and typically presents at an advanced stage with widespread lymph-node enlargement. What makes AITL distinctive is that it often behaves partly like an immune disorder — with fevers, rashes, and abnormal blood-test results — as well as a cancer. Because it is rare and can mimic infections or autoimmune disease, an expert pathology review is essential to confirm the diagnosis. Learn more on our lymphoma hub.
AITL belongs to the peripheral T-cell lymphoma (PTCL) family, but it is now recognised as its own distinct entity. Older classifications grouped many T-cell lymphomas together as "PTCL, not otherwise specified". Modern classification separates out AITL — along with a wider group of "nodal T-cell lymphomas with a follicular helper T-cell phenotype" — because it has a characteristic pattern under the microscope, its own molecular markers, and a distinct clinical behaviour. So AITL is a specific, named subtype within the broader peripheral T-cell lymphoma group, and it sits alongside other T-cell subtypes covered in our T-cell lymphoma overview.
AITL commonly presents with generalised swelling of lymph nodes in the neck, armpits, groin and inside the chest and abdomen. Because it involves the immune system directly, patients frequently also have so-called "B symptoms" — unexplained fevers, drenching night sweats and weight loss — along with skin rashes or itching, an enlarged liver and spleen, and swelling of the body. Blood tests may show anaemia and abnormal antibodies. These immune-like features mean AITL can be mistaken at first for an infection or an autoimmune condition. Any lymph-node swelling that persists beyond a few weeks, or is accompanied by fevers and night sweats, should be assessed promptly. You can book a free consultation with our team to review your reports.
The cornerstone of diagnosis is a surgical excision biopsy of an affected lymph node (a needle sample is often not enough for T-cell lymphomas). An expert haematopathologist then examines the tissue and runs immunohistochemistry to look for follicular helper T-cell markers such as CD10, BCL6, PD-1 and CXCL13, along with a characteristic proliferation of small blood vessels. Testing for Epstein-Barr virus (EBV) within the tumour is also standard. Staging then uses PET-CT and a bone-marrow examination to map the full extent of disease. At CION, biopsy, bone-marrow exam, molecular and immunohistochemistry testing, and tumour-board review are delivered directly. Read how staging feeds treatment on our Lymphoma Treatment in Hyderabad page.
Because AITL is usually diagnosed at an advanced stage, treatment is mainly systemic — combination chemotherapy that reaches disease throughout the body. Depending on the individual, this may be followed by consolidation to deepen and prolong the response. For fit patients who respond, an autologous stem-cell transplant is often considered to consolidate remission; transplant is arranged through accredited partner facilities (a coordinated referral), while CION delivers the chemotherapy, immunotherapy, supportive care and monitoring directly. Relapsed or resistant disease may be treated with different drug-class approaches or a clinical-trial option. We do not list specific drug or regimen names here — the exact regimen is individualised and explained on the Lymphoma Treatment in Hyderabad page. Every AITL case at CION is reviewed by a multidisciplinary tumour board before the plan is set.
AITL is an aggressive lymphoma and, as a group, T-cell lymphomas tend to have a less favourable outlook than the common B-cell lymphomas. For context, published series report Hodgkin lymphoma survival around 80–90% and diffuse large B-cell lymphoma around 60–70%, whereas most peripheral T-cell lymphomas including AITL sit meaningfully below that (per NCCN and ESMO). However, outcomes vary widely by individual — age, general fitness, stage, response to initial treatment and whether a transplant is possible all matter, and results for fit patients who reach a good remission can be considerably better than the group average. These figures are drawn from published series and are not CION-specific; your own outlook should be discussed with your oncologist. Talk to a specialist for a personalised assessment.
Many AITL biopsies contain EBV-positive B-cells within the tumour environment. The lymphoma itself is a T-cell cancer, but the disordered immune background of AITL allows EBV-driven B-cells to expand alongside it. This is one reason AITL can be confusing to diagnose, and occasionally a secondary EBV-related B-cell lymphoma can arise. Detecting EBV in the tissue is a routine part of the pathology work-up and supports the AITL diagnosis. It does not usually change the core treatment approach on its own, but it is one of the molecular features your haematopathologist looks for. Testing concepts like EBV status, CD10, PD-1 and CXCL13 are all part of confirming the subtype — see our T-cell lymphoma overview for how these subtypes are distinguished.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.